Finally, the synthetic DYRK1A inhibitor INDY, proven to modulate the phenotypic effects of DYRK1A overexpression in vivo [186], has been shown to improve the response of ovarian cancer spheroids to carboplatin [79]. The gene discussed is DYRK1A; the disease is ovarian carcinoma.